Christopher Richard Anzalone sold $1.8M of ARWR
Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC.. 26,031 shares at an average of $68.04, traded Dec 19, 2025, filed Dec 23, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.8M at market
- 0Share of holdings soldSold 0.7% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001423029-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -3,979 | $66.67 | $265k | 3,827,978 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -8,147 | $68.01 | $554k | 3,819,831 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -1,319 | $68.48 | $90k | 3,818,512 | Dec 23, 2025 |
| Dec 22, 2025 | SOpen-market sale Common Stock10b5-1 | -10,012 | $68.33 | $684k | 3,808,500 | Dec 23, 2025 |
| Dec 22, 2025 | SOpen-market sale Common Stock10b5-1 | -2,574 | $68.85 | $177k | 3,805,926 | Dec 23, 2025 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Patrick O'Brien COO | $3.1M 49,493 shares | -9% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $2.5M 40,164 shares | -19% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% | |
| 28Weak | ARROWHEAD PHARMACEUTICALS, INC. | Mauro Ferrari director | $527k 7,530 shares | -10% | |
| 35Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $677k 10,000 shares | -23% | |
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | William D. Waddill director | $566k 8,367 shares | -13% | |
| 36Weak | ARROWHEAD PHARMACEUTICALS, INC. | Victoria Vakiener director | $679k 10,040 shares | -22% | |
| 65Notable | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $5.4M 85,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.